ARTICLE | Product Development
Relmada data offer hope of safer option for depression
Relmada’s depression therapy may avoid the psychotomimetic effects of J&J’s esketamine, enabling at-home use
October 16, 2019 12:05 AM UTC
Updated on Oct 22, 2019 at 11:48 PM UTC
Relmada more than doubled its share price Tuesday after reporting Phase II data hinting that REL-1017 could be as effective at treating depression as J&J’s Spravato without the psychotomimetic side effects that require physician monitoring.
Relmada Therapeutics Inc. (NASDAQ:RLMD) shares gained $15.01 (134%) to $26.20 Tuesday before giving back some of the gains to finish up 83% at $19.81...
BCIQ Target Profiles